Kneyber Martin C J, Kimpen Jan L L
VU University Medical Center, Department of Paediatric Intensive Care, Office 8D11, PO Box 7057, 1007 MB Amsterdam, The Netherlands.
Curr Opin Investig Drugs. 2004 Feb;5(2):163-70.
Respiratory syncytial virus (RSV) is the most important causative agent of respiratory tract infections. Young children with chronic lung or congenital heart disease are at increased risk for severe disease. Intensive research into a candidate vaccine has yielded live attenuated vaccines and subunit vaccines, which have been studied in humans. Although immunogenic, occurrence of upper respiratory tract infection symptoms with live attenuated vaccine prohibits evaluation in young infants. Subunit vaccines include purified F protein (PFP-1 and -2) and BBG2Na. PFP vaccines are effective in seropositive children, but also induce upper respiratory symptoms. BBG2Na was being investigated in phase III clinical trials, however, further development has now been discontinued. This review discusses recent advances in RSV vaccine development.
呼吸道合胞病毒（RSV）是呼吸道感染最重要的病原体。患有慢性肺部疾病或先天性心脏病的幼儿患严重疾病的风险增加。对候选疫苗的深入研究已产生了减毒活疫苗和亚单位疫苗，这些疫苗已在人体中进行了研究。尽管具有免疫原性，但减毒活疫苗出现的上呼吸道感染症状禁止在幼儿中进行评估。亚单位疫苗包括纯化的F蛋白（PFP-1和-2）和BBG2Na。PFP疫苗对血清阳性儿童有效，但也会引发上呼吸道症状。BBG2Na正在进行III期临床试验，然而，目前已停止进一步开发。本综述讨论了RSV疫苗开发的最新进展。
